48 Participants Needed

AVR-48 for Safety Evaluation

SP
JW
Overseen ByJia W Chang, MD
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1
Sponsor: AyuVis Research, Inc.

Trial Summary

Will I have to stop taking my current medications?

Yes, you will need to stop taking any prescription or non-prescription medications, herbal remedies, or vitamin supplements starting 14 days before the first dose and throughout the study. However, acetaminophen (up to 2 grams per day) and hormone replacement therapy are allowed.

What is the purpose of this trial?

This is a Phase 1 (healthy adult volunteers), 2-part, double-blind, randomized, placebo controlled trial to evaluate the safety and pharmacokinetic (PK) profiles of escalating single doses of AVR-48 versus placebo (SAD) and escalating multiple doses of AVR-48 versus placebo (MAD). SAD will be initiated first and include a sentinel dosing design. MAD will not utilize a sentinel design unless the safety monitoring committee requests the addition of sentinels. The MAD will be initiated once the lowest doses from SAD are deemed safe.

Research Team

SA

Suchismita Acharya, PhD

Principal Investigator

AyuVis Research, Inc.

Eligibility Criteria

This trial is for healthy adult volunteers interested in testing a new medication, AVR-48. Participants must meet certain health standards but specific inclusion and exclusion criteria are not detailed here.

Inclusion Criteria

Provision of signed and dated informed consent form (ICF)
Stated willingness to comply with all study procedures and availability for the duration of the study
I haven't smoked or used nicotine products for at least 3 months.
See 7 more

Exclusion Criteria

History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study
Positive result at screening for tuberculosis (i.e., positive result for QuantiFERON TB-Gold)
I have a significant health or mental condition.
See 13 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Single Ascending Dose (SAD)

Participants receive a single IV dose of AVR-48 or placebo in a sentinel dosing design

1 week
Multiple visits for dosing and monitoring

Multiple Ascending Dose (MAD)

Participants receive multiple IV doses of AVR-48 or placebo over 7 days

1 week
Daily visits for dosing and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks
1 follow-up visit 7 days after last dose

Treatment Details

Interventions

  • AVR-48
Trial Overview AVR-48's safety and how it moves through the body (pharmacokinetics) are being tested against a placebo. The study has two parts: one with single escalating doses (SAD) and another with multiple ascending doses (MAD), both compared to a placebo.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug: AVR-48Experimental Treatment1 Intervention
AVR-48 is a small molecule with TLR4 modulating activity and macrophage modulator
Group II: Drug: PlaceboPlacebo Group1 Intervention
0.9% saline

Find a Clinic Near You

Who Is Running the Clinical Trial?

AyuVis Research, Inc.

Lead Sponsor

Trials
1
Recruited
50+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security